Back to Top

Annemieke DeMaggio's blog

0 comments
Submitted by Annemieke DeMaggio on Thu, 07/30/2020 - 10:15

Osimertinib granted FDA BTD for adjuvant treatment of resectable, EGFRmut NSCLC

News

Interim analysis of the phase 3 ADAURA study showed a significant improvement in DFS, and study was unblinded early in April 2020 (AZ press release)

Osimertinib
EGFR
NSCLC

Pages

Subscribe to RSS - Annemieke DeMaggio's blog
BLU Ampersand, Inc.

Copyright 2013-2019 BLU Ampersand, Inc. All rights reserved. ©
iNFOGENiUS® & iNFOwizard® are registered trademarks.